EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

• Hauptverfasser: Emily Capone (Verfasst von), Rossano Lattanzio (Verfasst von), Fabio Gasparri (Verfasst von), Paolo Orsini (Verfasst von), Cosmo Rossi (Verfasst von), Valentina Iacobelli (Verfasst von), Vincenzo De Laurenzi (Verfasst von), Pier Giorgio Natali (Verfasst von), Barbara Valsasina (Verfasst von), Stefano Iacobelli (Verfasst von), Gianluca Sala (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2021-04-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

HER-3 is becoming an attractive target for antibody-drug conjugate (ADC)-based therapy. Indeed, this receptor and its ligands are found to be overexpressed in several malignancies, and re-activation of its downstream signaling axis is known to play a critical role in modulating the sensitivity of ta...